PAVmed Inc. PAVM

Company Overview

PAVmed Inc. is a diversified commercial-stage medical technology company focused on developing, acquiring, and commercializing healthcare products and technologies across multiple clinical areas. The company operates primarily in the medical device and digital health industries, with activities spanning minimally invasive technologies, diagnostics, cancer detection, and healthcare infrastructure solutions. PAVmed’s business model combines internal product development with majority-controlled subsidiaries that pursue targeted commercialization strategies in specialized healthcare markets.

The company’s primary revenue drivers and strategic focus have centered on its ownership interests in Lucid Diagnostics Inc., which develops esophageal precancer detection technologies, and Veris Health Inc., a digital health and remote patient monitoring platform. Historically, PAVmed also developed products in areas such as infusion therapy and gastrointestinal technologies. Founded in 2014 by medical device entrepreneur Lishan Aklog, the company evolved from a single-product development platform into a holding-company-style healthcare technology organization with multiple operating subsidiaries and public market financing relationships.

Business Operations

PAVmed generates revenue primarily through commercial activities associated with its operating subsidiaries, licensing arrangements, product sales, and strategic healthcare technology investments. Its largest operating asset has been Lucid Diagnostics, which markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer associated with Barrett’s Esophagus and esophageal adenocarcinoma. Through Veris Health, the company has pursued remote patient monitoring technologies intended to support oncology care and chronic disease management using connected digital health infrastructure.

The company’s operations are concentrated mainly in the United States, though certain technologies and intellectual property strategies have international relevance. PAVmed controls proprietary medical technologies, patents, and commercialization rights through its subsidiaries and affiliated entities. Historically disclosed partnerships and strategic relationships have included collaborations with healthcare systems, diagnostic laboratories, and clinical research organizations supporting commercialization and validation efforts. The company has also used public capital markets and subsidiary-level financing structures to support development activities and expansion initiatives.

Strategic Position & Investments

PAVmed’s strategic direction has focused on building a portfolio of healthcare technology assets with differentiated clinical utility and scalable commercialization potential. The company has emphasized minimally invasive diagnostics, preventive medicine, and digital health monitoring as core growth themes. A major component of this strategy has been the development and expansion of Lucid Diagnostics, including investments in clinical studies, reimbursement initiatives, laboratory infrastructure, and physician adoption programs intended to increase screening utilization for esophageal disease.

The company has also invested in digital health and remote monitoring through Veris Health, reflecting broader industry trends toward connected care and outpatient disease management. PAVmed has historically pursued acquisitions, incubations, and structured financings to expand its portfolio while maintaining operational alignment across subsidiaries. Public filings and investor materials have identified intellectual property development, reimbursement expansion, and commercialization scale-up as strategic priorities. Data regarding long-term profitability targets or future acquisition pipelines remains inconclusive based on available public sources.

Geographic Footprint

PAVmed is headquartered in New York, United States, and its operational footprint is primarily concentrated in the U.S. healthcare market. Commercial activities, clinical programs, and laboratory operations associated with Lucid Diagnostics are focused largely on domestic physician networks, healthcare systems, and screening programs. The company’s technologies are designed for broader applicability across developed healthcare markets, although publicly disclosed international commercial penetration has remained limited relative to larger multinational medical technology companies.

The company maintains influence primarily through its participation in the North American medical technology and diagnostics sectors, including relationships with clinical institutions, laboratory providers, and healthcare reimbursement stakeholders. While intellectual property protections may extend internationally, publicly verified operational infrastructure outside the United States has not been extensively disclosed in major filings.

Leadership & Governance

PAVmed was founded by Dr. Lishan Aklog, a cardiac surgeon and medical device entrepreneur who has played a central role in shaping the company’s acquisition-driven and subsidiary-focused strategy. The company’s leadership philosophy has emphasized capital-efficient innovation, commercialization of clinically differentiated technologies, and development of independent operating subsidiaries capable of accessing strategic financing and public capital markets.

Key executives and leadership figures include:

• Lishan Aklog – Chairman and Chief Executive Officer
• Brian deGuzman – Chief Financial Officer
• Sanjay Srivastava – President and Chief Operating Officer of Lucid Diagnostics
• Michael Dragutsky – Executive leadership roles associated with commercialization and operations within affiliated entities

Corporate governance and operational disclosures are primarily detailed through SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and investor presentations associated with both PAVmed and Lucid Diagnostics. Information regarding certain executive responsibilities and subsidiary reporting structures may vary across reporting periods due to organizational changes and financing activities.